Pharmacodynamics of combined estrogen-progestin oral contraceptives 3. Inhibition of ovulation

References

• Goldzieher JW, Rudel HW. How the oral contraceptives came to be developed. JAMA. 1974;230:421–425.
   PubMed Web of Science ®Google Scholar
• Kurzrok R. The prospects for hormonal sterilization. J Contraception. 1937;2:27–29.
   PubMedGoogle Scholar
• Sturgis SH, Albright F. Mechanism of estrin therapy in the relief of dysmenorrhea. Endocrinology. 1940;26:68–72.
   Google Scholar
• Pincus G, Chang MC. The effects of progesterone and related compounds on ovulation and early development in the rabbit. Acta Physiol Lat Am. 1953;3:177–183.
   PubMedGoogle Scholar
• Pincus G, Chang MC, Hafez ES, et al. Effects of certain 19-nor steroids on reproductive processes in animals. Science. 1956;124(3227):890–891.
   PubMed Web of Science ®Google Scholar
• Miyake T, Pincus G. Progestational activity of certain 19-norsteroids and progesterone derivatives. Endocrinology. 1958;63:816–824.
   PubMed Web of Science ®Google Scholar
• Pincus G, Rock J, Garcia CR. Effects of certain 19-nor steroids upon reproductive processes. Ann NY Acad Scie. 1958;71:677–690.
   PubMed Web of Science ®Google Scholar
• Pincus G. Some effects of progesterone and related compounds upon reproduction and early development in mammals. Acta Endocrinol (Kbh). 1956;23(Suppl 28):18–36.
   Google Scholar
• Garcia CR, Pincus G, Rock J. Effects of three 19-nor steroids on human ovulation and menstruation. Am J Obstet Gynecol. 1958;75:82–97.
   PubMed Web of Science ®Google Scholar
• Pincus G, Rock J, Garcia CR, et al. Fertility control with oral medication. Am J Obstet Gynecol. 1958;75:1333–1346.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW. Pharmacology of the ethynyl estrogens. In: Shoupe D, Haseltine F, editors. Contraception. New York: Springer Verlag New York Inc; 2011. p. 17.
   Google Scholar
• Goldzieher JW, Moses LE, Ellis LT. Study of norethindrone in contraception. JAMA. 1962;180:359–361.
   Web of Science ®Google Scholar
• Zeilmaker GH. The byphasic effect of progesterone on ovulation in the rat. Acta Endocrinol (Kbh). 1966;51:461–468.
   PubMedGoogle Scholar
• Everett JW. Progesterone end estrogen in the experimental control of ovulation time and other features of the estrous cycle in the rat. Endocrinology. 1948;43:389–405.
   PubMed Web of Science ®Google Scholar
• Harper MJK. The effect of chlormadinone on the response of the ovaries and uterus of the immature rat to gonadotropic stimulation. J Endocrinol. 1964;30:235–245.
   PubMed Web of Science ®Google Scholar
• McDonald PG, Gilmore DP. The effect of ovarian steroids on hypothalamic threshold in the female rat. J Endocrinol. 1971;49:421–429.
   PubMed Web of Science ®Google Scholar
• Mishell DR, Odell WD. Effect of varying doses of ethynodiol diacetate upon serum luteinizing hormone. Am J Obstet Gynecol. 1971;109:140–149.
   PubMed Web of Science ®Google Scholar
• Taymor ML. Effect of synthetic progestins on pituitary gonadotropin excretion. J Clin Endocrinol Metab. 1964;24:803–807.
   PubMed Web of Science ®Google Scholar
• Elstein M. Urinary hormone excretion patterns in chlormadinone acetate treated patients and the associated cervical mucus changes. In: Christie GA, Moore-Robinson M, editors. Chlormadinone acetate: a new departure in oral contraception. Amsterdam: Excerpta Med; 1969. p. 46–59.
   Google Scholar
• Lauweryns J, Ferin J. Effects of the ovary of prolonged administration of lynestrenol: a histological study. Int J Fertil. 1964;9:35–39.
   PubMedGoogle Scholar
• Larsson-Cohn U, Johannisson EDB, Wide L, et al. Effects of continuous daily administration of 0.5 mg of norethindrone on plasma levels of progesterone and on the urinary excretion of luteinizing hormone, pregnandiol and total oestrogens. Acta Endocrinol (Kbh). 1970;63:21624.
   Google Scholar
• Larsson-Cohn U, Johannisson EDB, Gemzell C. Effects of continuous daily administration of 0.3 mg of norethindrone on plasma levels of progesterone and on the urinary excretion of pregnandiol and total oestrogens. Acta Endocrinol (Kbh). 1970;64:38–46.
   PubMedGoogle Scholar
• Diczfalusy E, Goebelsmann U, Johannisson E, et al. Pituitary and ovarian function in women on continuous low-dose progestogens: effects of chlormadinone acetate and norethisterone. Acta Endocrinol (Kbh). 1969;62:679 93.
   PubMedGoogle Scholar
• Rudel HW, Martinez-Manutou J, Maqueo-Topete M. The role of progestogens in the hormonal control of fertility. Fertil Steril. 1965;16:158–169.
   PubMed Web of Science ®Google Scholar
• Van der Vies J. Biological activity evaluation of progestins. In: Benagiano G, Zulli P, Diczfalusy E, editors. Progestogens in therapy. New York: Raven Press; 1983. p. 39–50.
   Google Scholar
• Landgren BM, Diczfalusy E. Hormonal effects of the 300 microgram norethisterone (NET) minipill. I. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration. Contraception. 1980;21:87–113.
   PubMed Web of Science ®Google Scholar
• Diczfalusy E, Landgren BM. Low-dose progestogens and pituitary, ovarian and endometrial function. In: Benagiano G, Zulli P, Diczfalusy E, editors. Progestogens in therapy. New York: Raven Press; 1983. p. 133–155.
   Google Scholar
• Phillips A, Hahn DW, Klimek S, et al. A comparison of the potencies and activities of progestogens used in contraceptives. Contraception. 1987;36:181–192.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Gerlinger C, Richard S, et al. Ovulation inhibition doses of progestins: a systematic review of the available literature and of marketed preparations worldwide. Contraception. 2011;84:549–557.
   PubMed Web of Science ®Google Scholar
• West CP. Inhibition of ovulation with oral progestins – effectiveness in premenstrual syndrome. Eur J Obstet Gynecol Reprod Biol. 1990;34:11928.
   Web of Science ®Google Scholar
• Song S, Chen JK, Lu CH, et al. Effects of different doses of norethisterone on ovarian function, serum sex hormone binding globulin and high-density lipoprotein-cholesterol. Contraception. 1993;47:527–537.
   PubMed Web of Science ®Google Scholar
• Spona J, Schneider WH, Bieglmayer C, et al. Ovulation inhibition with different doses of levonorgestrel and other progestogens: clinical and experimental investigations. Acta Obstet Gynecol Scand. 1979;88(Suppl):7–15.
   Google Scholar
• Rice CF, Killick SR, Dieben T, et al. A comparison of the inhibition of ovulation achieved by desogestrel 75 μg and levonorgestrel 30 μg daily. Hum Reprod. 1999;14:982–985.
   PubMed Web of Science ®Google Scholar
• van der Vies J, de Visser J. Endocrinological studies with desogestrel. Arzneimittelforschung. 1983;33:231–236.
   PubMed Web of Science ®Google Scholar
• Cullberg G, Lindstedt G, Lundberg PA, et al. Central and peripheral effects of desogestrel 15-60 μg daily for 21 days in healthy female volunteers. Acta Obstet Gynecol Scand. 1982;111:21–28.
   Google Scholar
• Benagiano G, Primiero F. Seventy-five microgram desogestrel minipill, a new perspective in estrogen-free contraception. Ann NY Acad Scie. 2003;997:163–173.
   PubMed Web of Science ®Google Scholar
• Korver T, Klipping C, Heger-Mahn D, et al. Maintenance of ovulation inhibition with the 75-μg desogestrel-only contraceptive pill (Cerazette®) after scheduled 12-h delays in tablet intake. Contraception. 2005;71:8–13.
   PubMed Web of Science ®Google Scholar
• Spona J, Huber J. Pharmacological and endocrine profiles of gestodene. Int J Fertil. 1987;32(Suppl):6–14.
   PubMedGoogle Scholar
• Eyong E, Buchi K, Elstein M. Effects of 180 micrograms and 250 micrograms norgestimate on pituitary-ovarian function and cervical mucus. Fertil Steril. 1988;50:756–760.
   PubMed Web of Science ®Google Scholar
• Geil RG, Lamar JK. FDA studies of estrogen, progestogens, and estrogen/progestogen combinations in the dog and monkey. J Toxicol Environ Health. 1977;3:179–193.
   PubMed Web of Science ®Google Scholar
• Kwapien RP, Giles RC, Geil RG, et al. Malignant mammary tumors in beagle dogs dosed with investigational oral contraceptive steroids. J Natl Cancer Inst. 1980;65:137–144.
   PubMedGoogle Scholar
• Gutiérrez-Nájar A, Márquez-Monter H, Giner-Velázquez J, et al. Presence of corpus luteum as evidence of ovulation in women treated with low doses of chlormadinone acetate. Am J Obstet Gynecol. 1968;102:1018–1022.
   PubMed Web of Science ®Google Scholar
• Pelissier C, Blacker C, Feinstein MC, et al. Action anti-ovulatoire de l’acetate de chlormadinone [Antiovulatory action of chlormadinone acetate]. Contracept Fertil Sexual. 1994;22:37–40.
   PubMedGoogle Scholar
• Bazin B, Thevenot R, Bursaux C, et al. Effect of nomegestrol acetate, a new 19-nor-progesterone derivative, on pituitary-ovarian function in women. Br J Obstet Gynaecol. 1987;94:1199–1204.
   PubMedGoogle Scholar
• Couzinet B, Young J, Brailly S, et al. The antigonadotropic activity of progestins (19-nortestosterone and 19norprogesterone derivatives) is not mediated through the androgen receptor. J Clin Endocrinol Metab. 1996;81:4218–4223.
   PubMed Web of Science ®Google Scholar
• Couzinet B, Young J, Kujas M, et al. The antigonadotropic activity of a 19-nor-progesterone derivative is exerted both at the hypothalamic and pituitary levels in women. J Clin Endocrinol Metab. 1999;84:4191–4196.
   PubMed Web of Science ®Google Scholar
• Basdevant A, Pelissier C, Conard J, et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. Contraception. 1991;44:599–605.
   PubMed Web of Science ®Google Scholar
• Moore C, Carol W, Gräser T, et al. Influence of dienogest on ovulation in young fertile women. Clin Drug Invest. 1999;18:271–278.
   Web of Science ®Google Scholar
• Klipping C, Duijkers I, Remmers A, et al. Ovulation-inhibiting effects of dienogest in a randomized, dosecontrolled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52:1704–1713.
   PubMed Web of Science ®Google Scholar
• Hamilton CJ, Evers JL, Tan FE, et al. The reliability of ovulation prediction by a single ultrasonographic follicle measurement. Hum Reprod. 1987;2:103–107.
   PubMed Web of Science ®Google Scholar
• Hoogland HJ, Skouby SO. Ultrasound evaluation of ovarian activity under oral contraceptives. Contraception. 1993;47:583–590.
   PubMed Web of Science ®Google Scholar
• Rosenbaum P, Schmidt W, Helmerhorst FM, et al. Inhibition of ovulation by a novel progestogen (drospirenone) alone or in combination with ethinylestradiol. Eur J Contracept Reprod Health Care. 2000;5:16–24.
   PubMedGoogle Scholar
• Elger W, Beier S, Pollow K, et al. Conception and pharmacodynamic profile of drospirenone. Steroids. 2003;68:891–905.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Comparative pharmacology of newer progestogens. Drugs. 1996;51:188–215.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW. Estrogens in oral contraceptives: historical perspectives. Johns Hopkins Med J. 1982;150:165–169.
   PubMedGoogle Scholar
• Goldzieher JW. The history of steroidal contraceptive development: the estrogens. Perspect Biol Med. 1993;36:363–368.
   PubMed Web of Science ®Google Scholar
• Adler L. Zur Physiologie und Pathologie der Ovarialfunktion [On the physiology and pathology of ovarian function]. Arch Gynäkol. 1912;95:349–424.
   Google Scholar
• Iscovesco H. Les lipoides de l’ovaire [On ovarian lipoids]. Compt Rend Soc Biol. 1912;73:16–18.
   Google Scholar
• Fellner O. Experimentell erzeugte Wachstumsveränderungen am weiblichen Genitale der Kaninchen [Experimentally-generated growth changes in the female genitalia of rabbits]. Zentralbl Allg Pathol Anat. 1912;23:673–676.
   Google Scholar
• Allen E, Doisy EA An ovarian hormone: preliminary report on its localization, extraction, partial purification and action in test animals. JAMA. 1923;81:819–821.
   Google Scholar
• Fellner O. Ueber die Tätigkeit des ovarium in der Schwangerschaft (interstitiezellen Zellen) [On the activity of the ovary in pregnancy (interstitial cells)]. Monatschr Geburst Gynäkol. 1921;54:88–94.
   Google Scholar
• Fellner O. Die wirkung des Feminin auf das Ei [The effect of Feminin on the egg]. Med Klin. 1927;23:1527–1529.
   Google Scholar
• Reiprich W. Experimenteller Hyperfeminismus. Seine Bedeutunbg für weibliche generations organe und gestation [Experimental hyper feminism. Its importance for female reproductive organs and gestation]. Arch. Gynäkol. 1930;141:27–46.
   Google Scholar
• Lyon RA. Relief of essential dysmenorrhea with ethinyl estradiol. Surg Gynecol Obstet. 1943;77:657–660.
   Google Scholar
• Martinez-Manatou J, Gual C, Goldzieher JW, et al. Comparative antiovulatory potency of certain natural and synthetic estrogens. Presented at the 46th Annual meeting of the Endocrine Society, San Francisco, June 1964.
   Google Scholar
• Gual C, Becerra C, Rice-Wray E, et al. Inhibition of ovulation by estrogens. Am J Obstet Gynecol. 1967;97:443–447.
   PubMed Web of Science ®Google Scholar
• Goldzieher JW, Pena A, Chenault CB, et al. Comparative studies of the ethynyl estrogens used in oral contraceptives. II. Antiovulatory potency. Am J Obstet Gynecol. 1975;122:619–624.
   PubMed Web of Science ®Google Scholar
• Schwartz U, Schneller E, Moltz L, et al. Vaginal administration of ethinylestradiol: effects on ovulation and hepatic transcortin synthesis. Contraception. 1982;25:253–259.
   PubMed Web of Science ®Google Scholar
• Sitruk-Ware R, Nath A. Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pills. Best Pract Res Clin Endocrinol Metab. 2013;27:13–24.
   PubMed Web of Science ®Google Scholar
• Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
   Google Scholar
• Kuhnz W, Gansau C, Mahler M. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol. Arzneimittelforschung. 1993;43:966–973.
   PubMed Web of Science ®Google Scholar
• Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3–63.
   PubMed Web of Science ®Google Scholar
• Kuhnz W, Blode H, Zimmermann H. Pharmacokinetics of exogenous natural and synthetic estrogens and antiestrogens. In: Oettel M, Schillinger E, editors. Handbook of experimental pharmacology, estrogens and antiestrogens II. Berlin: Springer Verlag; 1999. p. 261–322.
   Google Scholar
• Greenblatt RB, Hernandez-Ayup S, Bohler CS. Estradiol pellet implantation for contraception. J Reprod Med. 1974;13:207–208.
   PubMed Web of Science ®Google Scholar
• Mueck AO, Seeger H, Wallwiener D. Endogenous estradiol metabolism during treatment with oral contraceptives. Int J Clin Pharmacol Ther. 2004;42:160–164.
   PubMed Web of Science ®Google Scholar
• Coelingh Bennink HJ, Skouby S, Bouchard P, et al. Ovulation inhibition by estetrol in an in vivo model. Contraception. 2008;77:186–190.
   PubMed Web of Science ®Google Scholar
• Matsumoto S, Ito T, Inoue S, et al. Norethisteronazetat und Äthinylöstradiol zur Hemmung der Ovulation [Inhibition of ovulation with norethisterone acetate and ethinyl estradiol]. Zentralbl Gynäkol. 1961;83:1485–1492.
   PubMedGoogle Scholar
• Artner J, Kratochwil A. Über den Wirkungsmechanismus der Ovulationsunterdrueckung durch “Anovlar” [On the mechanism of action of ovulation inhibition with “Anovlar”]. Bibl Gynaecol. 1965;32:171–182.
   PubMedGoogle Scholar
• Segre EJ, Henzl MR, Giner J, et al. Reduction of the oral contraceptive estrogen burden by alternate day estrogen administration. Contraception. 1975;12:155–174.
   PubMed Web of Science ®Google Scholar
• Chowdhury V, Joshi UM, Gopalkrishna K, et al. ‘Escape’ ovulation in women due to the missing of low dose combination oral contraceptive pills. Contraception. 1980;22:241–247.
   PubMed Web of Science ®Google Scholar
• Rossmanith WG, Wirth U, Gasser S, et al. Ovarielle Aktivität, Zyklusverhalten und Verträglichkeit bei niedrigdosierten oralen Kontrazeptiva: eine Vergleichsstudie.[Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study]. Zentralbl Gynakol. 1997;119:538–544.
   PubMedGoogle Scholar
• Fels H, Steward R, Melamed A, et al. Comparison of serum and cervical mucus hormone levels during hormone-free interval of 24/4 vs. 21/7 combined oral contraceptives. Contraception. 2013;87:732–737.
   PubMed Web of Science ®Google Scholar
• Cohen BL, Katz M. Pituitary and ovarian function in women receiving hormonal contraception. Contraception. 1979;20:475–487.
   PubMed Web of Science ®Google Scholar
• Taylor DR, Anthony FW, Dennis KJ. Suppression of ovarian function by microgynon 30 in day 1 and day 5 “starters”. Contraception. 1986;33:463–471.
   PubMed Web of Science ®Google Scholar
• Morris SE, Groom GV, Cameron ED, et al. Studies on low dose contraceptives: plasma hormone changes in relation to deliberate pill (microgynon 30) omission. Contraception. 1979;20:61–69.
   PubMed Web of Science ®Google Scholar
• Landgren B-M, Diczfalusy E. Hormonal consequences of missing the pill during the first two days of three consecutive artificial cycles. Contraception. 1984;29:437–446.
   PubMed Web of Science ®Google Scholar
• Gaspard UJ, Dubois M, Gillain D, et al. Ovarian function is effectively inhibited by a low-dose triphasic oral contraceptive containing ethinylestradiol and levonorgestrel. Contraception. 1984;29:305–318.
   PubMed Web of Science ®Google Scholar
• Spona J, Feichtinger W, Kindermann C, et al. Inhibition of ovulation by an oral contraceptive containing 100 micrograms levonorgestrel in combination with 20 micrograms ethinylestradiol. Contraception. 1996;54:299–304.
   PubMed Web of Science ®Google Scholar
• Coney P, Del Conte A. The effects on ovarian activity of a monophasic oral contraceptive with 100 μg levonorgestrel and 20 μg ethinyl estradiol. Am. J. Obstet. Gynecol. 1999;181:553–558.
   Web of Science ®Google Scholar
• Mall-Haefeli M, Werner-Zodrow I, Huber P, et al. Klinische und biochemische Resultate bei der Behandlung mit Marvelon - Einem neuen steroidalen Ovulationshemmer [Clinical and biochemical results during the treatment with Marvelon, a new oral contraceptive]. Geburtshilfe Frauenheilkd. 1982;42:215–222.
   PubMed Web of Science ®Google Scholar
• Jung-Hoffmann C, Heidt F, Kuhl H. Effect of two oral contraceptives containing 30 mcg ethinylestradiol and 75 mcg gestodene or 150 mcg desogestrel upon various hormonal parameters. Contraception. 1988;38:593–603.
   PubMed Web of Science ®Google Scholar
• De Leo V, Lanzetta D, Vanni AL, et al. Low estrogen oral contraceptives and the hypothalamo-pituitary axis. Contraception. 1991;44:155–161.
   PubMed Web of Science ®Google Scholar
• Killick SR, Fitzgerald C, Davis A. Ovarian activity in women taking an oral contraceptive containing 20 μg ethinyl estradiol and 150 μg desogestrel: effects of low estrogen doses during the hormone-free interval. Am J Obstet Gynecol. 1998;179:S18–S24.
   PubMed Web of Science ®Google Scholar
• Wenzl R, Bennink HC, Van Beek A, et al. Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17βestradiol. Fertil Steril. 1993;60:616–619.
   PubMed Web of Science ®Google Scholar
• Csemiczky G, Dieben T, Coelingh Bennink HJT, et al. The pharmacodynamic effects of an oral contraceptive containing 3 mg micronized 17 beta-estradiol and 0.150 mg desogestrel for 21 days, followed by 0.030 mg desogestrel only for 7 days. Contraception. 1996;54:333–338.
   PubMed Web of Science ®Google Scholar
• Schubert W, Cullberg G. Ovulation inhibition with 17 betaestradiol cyclo-octyl acetate and desogestrel. Acta Obstet. Gynecol. Scand. 1987;66:543–547.
   PubMed Web of Science ®Google Scholar
• Thomas KH, Vankrieken L. Inhibition of ovulation by a new low-dose monophasic contraceptive containing gestodene. Internat J Fertil. 1989;34(Suppl):10–21.
   PubMedGoogle Scholar
• Thomas KH, Vankrieken L. Inhibition of ovulation by low-dose monophase contraceptive containing gestodene. Am J Obstet Gynecol. 1990;163:1404–1410.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Wessel J, Rosenbaum P, et al. Plasma concentrations of endogenous hormones during one regular treatment cycle with a lowdose oral contraceptive and during two cycles with deliberate omission of two tablets. Gynecol Endocrinol. 2004;18:318–326.
   PubMed Web of Science ®Google Scholar
• Spona J, Elstein M, Feichtinger W, et al. Shorter pill-free interval in combined oral contraceptives decreases follicular development. Contraception. 1996;54:71–77.
   PubMed Web of Science ®Google Scholar
• Elomaa K, Lähteenmäki P. Ovulatory potential of preovulatory sized follicles during oral contraceptive treatment. Contraception. 1999;60:275–279.
   PubMed Web of Science ®Google Scholar
• Fitzgerald C, Elstein M, Spona J. Effect of age on the response of the hypothalamo-pituitary-ovarian axis to a combined oral contraceptive. Fertil Steril. 1999;71:1079–1084.
   PubMed Web of Science ®Google Scholar
• Sullivan H, Furniss H, Spona J. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 μg) and ethinyl estradiol (15 μg) on ovarian activity. Fertil Steril. 1999;72:115–120.
   PubMed Web of Science ®Google Scholar
• Shaw G, Killick S, Elstein M. Assessment of ovarian activity in a gestodene containing triphasic oral contraceptive. Br J Fam Plann. 1992;18:76–78.
   Google Scholar
• Egarter C, Putz M, Strohmer H, et al. Ovarian function during low-dose oral contraceptive use. Contraception. 1995;51:329–333.
   PubMed Web of Science ®Google Scholar
• Hedon B, Cristol P, Plauchut A, et al. Ovarian consequences of the transient interruption of combined oral contraceptives. Int J Fertil. 1992;37:270–276.
   PubMedGoogle Scholar
• Baerwald AR, Olatunbosun OA, Pierson RA. Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use. Contraception. 2004;70:371–377.
   PubMed Web of Science ®Google Scholar
• London RS, Chapdelaine A, Upmalis D, et al. Comparative contraceptive efficacy and mechanism of action of the norgestimate-containing triphasic oral contraceptive. Acta Obstet Gynecol Scand. 1992;156(Suppl):9–14.
   Web of Science ®Google Scholar
• Rabe T, Nitsche DC, Runnebaum B. The effects of monophasic and triphasic oral contraceptives on ovarian function and endometrial thickness. Eur J Contracept Reprod Health Care. 1997;2:39–51.
   PubMedGoogle Scholar
• LaGuardia KD, Shangold G, Fisher A, et al. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol. Contraception. 2003;67:431–437.
   PubMed Web of Science ®Google Scholar
• Creinin MD, Lippman JS, Eder SE, et al. The effect of extending the pill-free interval on follicular activity: triphasic norgestimate/35 μg ethinyl estradiol versus monophasic levonorgestrel/20 μg ethinyl estradiol. Contraception. 2002;66:147–152.
   PubMed Web of Science ®Google Scholar
• Spona J, Binder N, Höschen K, et al. Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles. Fertil Steril. 2010;94:1195–1201.
   PubMed Web of Science ®Google Scholar
• Chabbert-Buffet N, Chassard D, Ochsenbein E, et al. Inhibition of ovulation by NOMAC/E2, a novel monophasic oral contraceptive combining nomegestrol acetate and 17β-oestradiol: a double-blind, randomised, dose-finding pilot study. Eur J Contracept Reprod Health Care. 2011;16:76–84.
   PubMed Web of Science ®Google Scholar
• Christin-Maitre S, Serfaty D, Chabbert-Buffet N, et al. Comparison of a 24-day and a 21-day pill regimen for the novel combined oral contraceptive, nomegestrol acetate and 17βestradiol (NOMAC/E2): a double-blind, randomized study. Hum Reprod. 2011;26:1338–1347.
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Klipping C, Grob P, et al. Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17 beta-oestradiol on ovarian function in comparison to a monophasic combined oral contraceptive containing drospirenone and ethinyl estradiol. Eur J Contracept Reprod Health Care. 2010;15:314–325.
   PubMed Web of Science ®Google Scholar
• Spona J, Huber J, Schmidt JB. Inhibierung der Ovulation mit 35 μg Athinylöstradiol und 2 mg Cyproteronazetat (Diane®-35) [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)]. Geburtshilfe Frauenheilkd. 1986;46:4358.
   Web of Science ®Google Scholar
• Pérez-Campos EF. Ethinylestradiol/dienogest in oral contraception. Drugs. 2010;70:681–689.
   PubMed Web of Science ®Google Scholar
• Spona J, Feichtinger W, Kindermann C, et al. Modulation of ovarian function by an oral contraceptive containing 30 micrograms ethinyl estradiol in combination with 2.00 mg dienogest. Contraception. 1997;56:185–191.
   PubMed Web of Science ®Google Scholar
• Teichmann A. Pharmacology of estradiol valerate/dienogest. Climacteric. 2003;6:17–23.
   PubMedGoogle Scholar
• Endrikat J, Parke S, Trummer D, et al. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open label studies. Contraception. 2008;78:218–225.
   PubMed Web of Science ®Google Scholar
• Lobo RA, Stanczyk FZ. New knowledge in the physiology of hormonal contraceptives. Am J Obstet Gynecol. 1994;170:1499–1507.
   PubMed Web of Science ®Google Scholar
• Endrikat J, Parke S, Trummer D, et al. Pituitary, ovarian and additional contraceptive effects of an estradiol based combined oral contraceptive: results of a randomized, open-label study. Contraception. 2013;87:227–234.
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29–38.
   PubMed Web of Science ®Google Scholar
• Willis SA, Kuehl TJ, Spiekerman AM, et al. Greater inhibition of the pituitary-ovarian axis in oral contraceptive regimens with a shortened hormone-free interval. Contraception. 2006;74:100–103.
   PubMed Web of Science ®Google Scholar
• Klipping C, Duijkers I, Trummer D, et al. Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen. Contraception. 2008;78:16–25.
   PubMed Web of Science ®Google Scholar
• Duijkers IJ, Klipping C, Zimmerman Y, et al. Inhibition of ovulation by administration of estetrol in combination with drospirenone or levonorgestrel: results of a phase II dose-finding pilot study. Eur J Contracept Reprod Health Care. 2015;20:476–489.
   PubMed Web of Science ®Google Scholar